drugset / Trial / NCT00073164

Depakote ER Plus an Atypical Antipsychotic Vs. an Atypical Antipsychotic Alone in the Treatment of Schizophrenia

NCT00073164

Phase 2 Completed 400 enrolled Abbott
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to assess the 14-day and 12-week safety and efficacy of Depakote ER used in combination with either olanzapine or risperidone versus antipsychotic monotherapy with olanzapine or risperidone for the treatment of schizophrenia.

Timeline

Start
2003-07
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Divalproex Sodium Small molecule
Subject Olanzapine Small molecule
Subject Risperidone Other / unclassified

Indications